JFG
BMRN icon

Jefferies Financial Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Jefferies Financial Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,600
Closed -$495K – 1710
2023
Q3 		$495K Buy
5,600
+600
+12% +$53.4K ﹤0.01% 1063
2023
Q2 		$433K Sell
5,000
-5,000
-50% -$471K ﹤0.01% 1225
2023
Q1 		$972K Buy
+10,000
New +$1.04M 0.01% 905

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Jefferies Financial Group's BMRN Position: Q2 2026 in Review

Jefferies Financial Group reduced its BioMarin Pharmaceuticals (BMRN) stake by 0.4% in Q2 2026, selling an estimated $103K and leaving 466,258 shares worth $26.7M. The position accounts for 0.18% of the portfolio, ranked #113.

Jefferies Financial Group first reported a position in BMRN in Q4 2022 and has held it in 11 quarters since. The position peaked at $27.8M in Q4 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Jefferies Financial Group held 466,258 shares of BioMarin Pharmaceuticals worth $26.7M as of Q2 2026.
  • Jefferies Financial Group sold 1,888 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $103K.
  • BioMarin Pharmaceuticals made up 0.18% of Jefferies Financial Group's portfolio in Q2 2026, its #113 holding.
  • Jefferies Financial Group first reported a position in BioMarin Pharmaceuticals in Q4 2022 and has held it in 11 quarters since.
  • Jefferies Financial Group's BioMarin Pharmaceuticals position peaked at $27.8M in Q4 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.